These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9552085)

  • 1. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy.
    Rajkumar SV; Gertz MA; Kyle RA
    Am J Med; 1998 Mar; 104(3):232-7. PubMed ID: 9552085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary systemic amyloidosis with delayed progression to multiple myeloma.
    Rajkumar SV; Gertz MA; Kyle RA
    Cancer; 1998 Apr; 82(8):1501-5. PubMed ID: 9554527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Polyneuropathy is an early finding in primary systemic amyloidosis].
    Romi F; Vedeler C; Tysnes OB; Mørk S; Aarli JA
    Tidsskr Nor Laegeforen; 2000 Apr; 120(11):1291-3. PubMed ID: 10868089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary systemic amyloidosis--a diagnostic primer.
    Gertz MA; Kyle RA
    Mayo Clin Proc; 1989 Dec; 64(12):1505-19. PubMed ID: 2513459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary amyloidosis presenting as upper limb multiple mononeuropathies.
    Tracy JA; Dyck PJ; Dyck PJ
    Muscle Nerve; 2010 May; 41(5):710-5. PubMed ID: 20405503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myopathy in primary systemic amyloidosis.
    Gertz MA; Kyle RA
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):655-60. PubMed ID: 8648333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transthyretin amyloid neuropathy has earlier neural involvement but better prognosis than primary amyloid counterpart: an answer to the paradox?
    Loavenbruck AJ; Singer W; Mauermann ML; Sandroni P; B Dyck PJ; Gertz M; Klein CJ; Low PA
    Ann Neurol; 2016 Sep; 80(3):401-11. PubMed ID: 27422051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial amyloidosis: a study of 52 North American-born patients examined during a 30-year period.
    Gertz MA; Kyle RA; Thibodeau SN
    Mayo Clin Proc; 1992 May; 67(5):428-40. PubMed ID: 1405768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idiopathic AA amyloidosis manifested by autonomic neuropathy, vestibulocochleopathy, and lattice corneal dystrophy.
    Tsunoda I; Awano H; Kayama H; Tsukamoto T; Ueno S; Fujiwara T; Watanabe M; Yamamoto T
    J Neurol Neurosurg Psychiatry; 1994 May; 57(5):635-7. PubMed ID: 8201343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinicopathological spectrum of renal amyloidosis.
    Hsu JY; Shu KH; Chan LP; Lu YS; Cheng CH; Sheu SS; Lian JD
    Zhonghua Yi Xue Za Zhi (Taipei); 1994 Oct; 54(4):230-9. PubMed ID: 7982133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study.
    Mahmood S; Bridoux F; Venner CP; Sachchithanantham S; Gilbertson JA; Rowczenio D; Wagner T; Sayed R; Patel K; Fontana M; Whelan CJ; Lachmann HJ; Hawkins PN; Gillmore JD; Wechalekar AD
    Lancet Haematol; 2015 Jun; 2(6):e241-50. PubMed ID: 26688234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teaching neuroimages: dyspnea as a presenting manifestation of amyloid myopathy.
    Ghosh PS; Thaera GM; Tracy JA
    Neurology; 2013 Dec; 81(24):e184. PubMed ID: 24323446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloidosis: review of 236 cases.
    Kyle RA; Bayrd ED
    Medicine (Baltimore); 1975 Jul; 54(4):271-99. PubMed ID: 1152671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic light-chain amyloidosis presenting with rapid progressive heart failure.
    Sunbul M; Durmus E; Kivrak T; Besiroglu F; Gerin F; Sari I; Mutlu B
    Ther Adv Cardiovasc Dis; 2013 Aug; 7(4):224-7. PubMed ID: 23868674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical manifestations at diagnosis in Japanese patients with systemic AL amyloidosis: a retrospective study of 202 cases with a special attention to uncommon symptoms.
    Matsuda M; Katoh N; Ikeda S
    Intern Med; 2014; 53(5):403-12. PubMed ID: 24583427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience.
    Cowan AJ; Skinner M; Seldin DC; Berk JL; Lichtenstein DR; O'Hara CJ; Doros G; Sanchorawala V
    Haematologica; 2013 Jan; 98(1):141-6. PubMed ID: 22733017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axoval neuropathy as initial manifestation of primary amyloidosis: report of a case submitted to bone marrow transplantation.
    Barsottini OG; Arantes A; Sigulem D; Kutner JM; Ribeiro AA; Moura LA; Hamerschlak N
    Arq Neuropsiquiatr; 2004 Sep; 62(3A):725-9. PubMed ID: 15334239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary AL (kappa-light chain) amyloidosis manifesting as peripheral neuropathy in a young male without increase in serum and urine immunoglobulin load: a diagnostic challenge.
    Sarkar C; Chand Sharma M; Nayak A; Mercy Ralte A; Gupta V; Singh S; Behari M
    Clin Neuropathol; 2005; 24(3):118-25. PubMed ID: 15943163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary systemic amyloidosis: response and survival in 64 patients.
    Gertz MA; Kyle RA
    Medicine (Baltimore); 1991 Jul; 70(4):246-56. PubMed ID: 2067409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.